Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Study of Mycobacterium w in BCG Refractory Superficial Transitional Cell Carcinoma of Bladder (STCC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00694798
Recruitment Status : Completed
First Posted : June 11, 2008
Last Update Posted : May 3, 2012
Information provided by (Responsible Party):
Cadila Pharnmaceuticals

Brief Summary:
The primary purpose of this study is to evaluate the response rate of this treatment (Mw) in patients with BCG refractory superficial transitional cell carcinoma. Other objectives include detecting the effect of Mw on Time to Tumor progression and evaluating safety.

Condition or disease Intervention/treatment Phase
Bladder Cancer Biological: Mycobacterium w Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 22 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Open Label, Single Arm, Exploratory Phase I Clinical Trial to Evaluate Efficacy and Safety of Mycobacterium w (Mw) in BCG Refractory Superficial Transitional Cell Carcinoma
Study Start Date : October 2008
Actual Primary Completion Date : July 2011
Actual Study Completion Date : July 2011

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Mw
All enrolled patients to receive Mycobacterium w
Biological: Mycobacterium w

Primary Outcome Measures :
  1. Response Rate [ Time Frame: 15 Months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Informed Consent obtained & signed:

    Ability to understand and the willingness to sign a written informed consent document.

  2. Disease characteristics:

    Patients with BCG refractory superficial transitional cell carcinoma, refractory carcinoma in situ, multiple unresected T1 and Ta high grade.

    BCG-refractory STCC is defined as when there is failure to achieve disease-free state at six months after initiation of BCG therapy either as primary or repeat therapy or recurrence of tumor within three months of completion of adequate induction or maintenance therapy or adequate retreatment. .

  3. Patient Characteristics:

Age: 18 completed years and above Performance status: ECOG 0-2 Life expectancy: At least 24 weeks Hematopoietic:Hemoglobin ≥ 9.0 g/dL


  • No patient who has eczema will be allowed to participate in this study.
  • Patients who are immuno-compromised will not be enrolled.
  • Patients with severe hepatic dysfunctions or with evidence of Cirrhosis will not be enrolled.
  • Patients with uncontrolled diabetes mellitus will not be enrolled in the study.

Note: The effects of Investigational product on the developing human fetus at the recommended therapeutic dose are unknown. For this reason and because other therapeutic agents used in this trial are known to be teratogenic, women of child bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.

Exclusion Criteria:

  • Patients who have had cytotoxic chemotherapy or radiotherapy prior to entering the study.
  • Intractable urinary tract infection.
  • No patient who has eczema should be allowed to participate in this study.
  • Patients who are immuno-compromised should not be enrolled.
  • Patients with severe hepatic dysfunctions or evidence of Cirrhosis should not be enrolled.
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to agents used in the study.
  • Pregnant women or nursing women are excluded from this study because agents used in the study have potential for teratogenic or abortifacient effects. Because there is known potential risk for adverse events in nursing infants secondary to treatment of the mother with investigational agent, breastfeeding should be discontinued if the mother is treated with investigational product.
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmias, or psychiatric illness/social situations that would limit compliance with study requirements.
  • Previous splenectomy
  • Clinically significant active infection
  • Patients with uncontrolled diabetes mellitus.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00694798

Show Show 17 study locations
Sponsors and Collaborators
Cadila Pharnmaceuticals
Layout table for investigator information
Principal Investigator: Mahesh Desai, MD Muljibhai Patel Urological Hospital
Principal Investigator: Amillal Bhat, MD S P Medical College & AG of Hospital
Principal Investigator: Sushil Bhatia, MD Choithram Hospital and Research Centre
Principal Investigator: Kim Mammen, MD Christian Medical College, Vellore, India
Principal Investigator: Ketan Rajyaguru, MD Siddhi Vinayak Hospital
Principal Investigator: Gaurang Gandhi, MD Gandhi Urocare
Principal Investigator: Kapil Thakkar, MD Excel Hospital
Principal Investigator: B. R. Shrivastav, MD Cancer Hospital & Research Institute
Principal Investigator: Anup Kundu, MD IPGMER, S.S.K.M. Hospital
Principal Investigator: Jitendra Amlani, MD Urocare Hospital
Principal Investigator: Rasesh Desai, MD Desai Urological and Maternity Hospital
Principal Investigator: N. K. Mohanty, MD V. M. Medical College and Safdarjang hospital
Principal Investigator: Shrawan K. Singh, MD Post Graduate Institute of Medical Education and Research
Principal Investigator: Ketan Shukla, MD Aarogyam Speciality Hospital
Principal Investigator: Krishna Moorhty, MD Lourdes hospital
Principal Investigator: Rajeev Sood, MD Dr. Ram Manohar Lohia Hospital and PGIMER
Principal Investigator: Purshottam K. Puri, MD Indira Gandhi Medical College, Shimla
Layout table for additonal information
Responsible Party: Cadila Pharnmaceuticals Identifier: NCT00694798    
Other Study ID Numbers: CR-80/8230
First Posted: June 11, 2008    Key Record Dates
Last Update Posted: May 3, 2012
Last Verified: May 2012
Keywords provided by Cadila Pharnmaceuticals:
Superficial Transitional Cell Carcinoma- BCG refractor
Additional relevant MeSH terms:
Layout table for MeSH terms
Carcinoma, Transitional Cell
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type